Aibing Xu
Impact in
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis
-
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 5
-
- Ubiquitin and proteasome pathways 1
- Glycosylation and Glycoproteins Research 1
- Co-authors
- Yuxian Bai (4 shared papers)Siyuan Tian (2 shared papers)Hongyu Cai (1 shared paper)Jian Wu (2 shared papers)Li Bai (2 shared papers)Baiyong Li (2 shared papers)Guoliang Shao (2 shared papers)Meili Sun (2 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)Cancer Science (1 paper)BioMed Research International (1 paper)Annals of Oncology (1 paper)Frontiers in Immunology (1 paper)
- Partner nations
- China
In The Last Decade
Aibing Xu
10 papers receiving 187 citations
Peers
Comparison fields: 5 of 36
- Hepatology 73
- Oncology 56
- Cancer Research 30
- Pathology and Forensic Medicine 29
- Pulmonary and Respiratory Medicine 25
Countries citing papers authored by Aibing Xu
This map shows the geographic impact of Aibing Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aibing Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aibing Xu more than expected).
Fields of papers citing papers by Aibing Xu
This network shows the impact of papers produced by Aibing Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aibing Xu. The network helps show where Aibing Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Aibing Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 35 | |
| 2 | 2020 | 32 | |
| 3 | 2021 | 31 | |
| 4 | Expression of leucine aminopeptidase 3 (LAP3) correlates with prognosis and malignant development of human hepatocellular carcinoma (HCC). | 2014 | 28 |
| 5 | 2020 | 24 | |
| 6 | 2020 | 19 | |
| 7 | 2020 | 8 | |
| 8 | 2024 | 5 | |
| 9 | [Combined three-dimensional conformal radiotherapy plus transcatheter arterial chemoembolization and surgical intervention for portal vein tumor thrombus in patients with hepatocellular carcinoma]. | 2011 | 5 |
| 10 | 2023 | 1 |
About Aibing Xu
Aibing Xu is a scholar working on Hepatology, Molecular Biology, Oncology, Cancer Research and Pathology and Forensic Medicine, having authored 10 papers that have together received 188 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Cancer Mechanisms and Therapy (2 papers), Lung Cancer Research Studies (2 papers), Cancer-related molecular mechanisms research (2 papers), Ferroptosis and cancer prognosis (1 paper), Ubiquitin and proteasome pathways (1 paper), Glycosylation and Glycoproteins Research (1 paper) and Peptidase Inhibition and Analysis (1 paper). The work is most often cited by research in Hepatology (73 citations), Oncology (56 citations), Cancer Research (30 citations), Pathology and Forensic Medicine (29 citations) and Pulmonary and Respiratory Medicine (25 citations). Aibing Xu has collaborated with scholars based in China. Frequent co-authors include Yuxian Bai, Siyuan Tian, Hongyu Cai, Jian Wu, Li Bai, Baiyong Li, Guoliang Shao, Meili Sun, Yilong Zhou and Yuan Zhou. Their work appears in journals such as Journal of Clinical Oncology, Cancer Science, BioMed Research International, Annals of Oncology and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.